Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin safety study in cirrhosis
ACTRN12620001076965Phase 2Not yet recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of empagliflozin in Cirrhosis and Portal Hypertension (PH) (3 arms), sponsored by St Vincent's Hospital. Primary endpoints: Adverse events and Empagliflozin pharmacokinetics. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on ACTRN12620001076965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001076965.